Pentraxin 3 and other inflammatory factors in central retinal vein occlusion and macular edema

Retina

Volumn 34, Issue 2, 2014, Pages 352-359

  Noma, Hidetaka ^a   Mimura, Tatsuya ^b   Masahara, Hidetaka ^c   Shimada, Katsunori ^d  

^a Tokyo Women s Medical University   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Eguchi Eye Hospital   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Central retinal vein occlusion; Interleukin 6; Macular edema; Monocyte chemotactic protein 1; Pentraxin 3; Soluble intercellular adhesion molecule 1; Soluble VEGF receptor 2; Vascular endothelial growth factor

Indexed keywords

ACUTE-PHASE PROTEINS; AGED; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MACULAR EDEMA; MALE; RETINAL VEIN OCCLUSION; SERUM AMYLOID P-COMPONENT; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VITRECTOMY; VITREOUS BODY;

EID: 84895074218     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182993d74     Document Type: Article

References (55)

1. Tsujikawa A, Ogura Y, Hiroshiba N, et al. In vivo evaluation of leukocyte dynamics in retinal ischemia reperfusion injury. Invest Ophthalmol Vis Sci 1998;39: 793-800.
2. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127: 1101-1114.
3. Miyake K, Miyake T, Kayazawa F. Blood-aqueous barrier in eyes with retinal vein occlusion. Ophthalmology 1992;99: 906-910.
4. Noma H, Funatsu H, Mimura T, Shimada K. Visual acuity and foveal thickness after vitrectomy for macular edema. Ophthalmologica 2010;224: 367-373.
5. Lu M, Perez VL, Ma N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci 1999; 40: 1808-1812.
6. Zhang SX, Wang JJ, Gao G, et al. Pigment epitheliumderived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006;20: 323-325.
7. Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009;4:e8158.
8. Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 2009; 116: 87-93.
9. Noma H, Funatsu H, Mimura T, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Curr Eye Res 2011;36: 256-263.
10. Noma H, Funatsu H, Harino S, et al. Vitreous inflammatory factors in macular edema with central retinal vein occlusion. Jpn J Ophthalmol 2011;55: 248-255.
11. Breviario F, d'Aniello EM, Golay J, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992;267: 22190-22197.
12. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23: 337-366.
13. Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102: 636-641.
14. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110: 2349-2354.
15. Alles VV, Bottazzi B, Peri G, et al. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 1994;84: 3483-3493.
16. Introna M, Alles VV, Castellano M, et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 1996;87: 1862-1872.
17. Goodman AR, Levy DE, Reis LF, Vilcek J. Differential regulation of TSG-14 expression in murine fibroblasts and peritoneal macrophages. J Leukoc Biol 2000;67: 387-395.
18. Doni A, Peri G, Chieppa M, et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 2003;33: 2886-2893.
19. Klouche M, Peri G, Knabbe C, et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 2004;175: 221-228.
20. Toniatti C, Demartis A, Monaci P, et al. Synergistic transactivation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. EMBO J 1990;9: 4467-4475.
21. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111: 1805-1812.
22. Souza DG, Soares AC, Pinho V, et al. Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol 2002;160: 1755-1765.
23. Souza DG, Amaral FA, Fagundes CT, et al. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am J Pathol 2009;174: 1309-1318.
24. Tachi N, Hashimoto Y, Ogino N. Vitrectomy for macular edema combined with retinal vein occlusion. Doc Ophthalmol 1999;97: 465-469.
25. Leizaola-Fernandez C, Suarez-Tata L, Quiroz-Mercado H, et al. Vitrectomy with complete posterior hyaloid removal for ischemic central retinal vein occlusion: series of cases. BMC Ophthalmol 2005;5:10.
26. Furukawa M, Kumagai K, Ogino N, et al. Long-term visual outcomes of vitrectomy for cystoid macular edema due to nonischemic central retinal vein occlusion. Eur J Ophthalmol 2006;16: 841-846.
27. The Central Vein Occlusion Study. Baseline and early natural history report. Arch Ophthalmol 1993;111: 1087-1095.
28. The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 1995;102: 1425-1433.
29. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;115: 486-491.
30. Han IC, Jaffe GJ. Comparison of spectral- and time-domain optical coherence tomography for retinal thickness measurements in healthy and diseased eyes. Am J Ophthalmol 2009;147: 847-858e1.
31. Otani T, Kishi S. Tomographic assessment of vitreous surgery for diabetic macular edema. Am J Ophthalmol 2000;129: 487-494.
32. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116: 73-79.
33. Noma H, Funatsu H, Mimura T, et al. Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion. Br J Ophthalmol 2011;95: 788-792.
34. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146: 1029-1039.
35. Deban L, Russo RC, Sironi M, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010; 11: 328-334.
36. Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000;156: 1733-1739.
37. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44: 2155-2162.
38. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113: 1538-1544.
39. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16: 4604-4613.
40. Pages G, Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene-a concert of activating factors. Cardiovasc Res 2005;65: 564-573.
41. Ghosh S, Baltimore D. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature 1990;344: 678-682.
42. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98: 2018-2026.
43. He H, Venema VJ, Gu X, et al. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 1999;274: 25130-25135.
44. Olivera A, Edsall L, Poulton S, et al. Platelet-derived growth factor-induced activation of sphingosine kinase requires phosphorylation of the PDGF receptor tyrosine residue responsible for binding of PLCgamma. FASEB J 1999;13: 1593-1600.
45. Wu LW, Mayo LD, Dunbar JD, et al. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 2000;275: 5096-5103.
46. Basile A, Sica A, d'Aniello E, et al. Characterization of the promoter for the human long pentraxin PTX3. Role of NFkappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem 1997;272: 8172-8178.
47. Liu H, Ren JG, Cooper WL, et al. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci U S A 2004;101: 6605-6610.
48. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118: 2041-2049.
49. Kriechbaum K, Michels S, Prager F, et al. Intravitreal avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92: 518-522.
50. Stefansson E, Novack RL, Hatchell DL. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 1990;31: 284-289.
51. Stefansson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 2006;51: 364-380.
52. Okunuki Y, Usui Y, Katai N, et al. Relation of intraocular concentrations of inflammatory factors and improvement of macular edema after vitrectomy in branch retinal vein occlusion. Am J Ophthalmol 2011;151:610-616 e1.
53. Raszewska-Steglinska M, Gozdek P, Cisiecki S, et al. Pars plana vitrectomy with ILM peeling for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 2009;19: 1055-1062.
54. Baharivand N, Hariri A, Javadzadeh A, et al. Pars plana vitrectomy and internal limiting membrane peeling for macular edema secondary to retinal vein occlusion. Clin Ophthalmol 2011;5: 1089-1093.
55. Noma H, Mimura T, Shimada K. Changes of macular sensitivity and morphology after pars plana vitrectomy for macular edema with central retinal vein occlusion: a case series. BMC Ophthalmol 2013;13:2.